Hämostaseologie,
Journal Year:
2025,
Volume and Issue:
45(01), P. 014 - 023
Published: Feb. 1, 2025
Abstract
Chimeric
antigen
receptor
(CAR)
T
cell
therapy
has
revolutionized
cancer
immunotherapy,
particularly
for
hematological
malignancies.
This
personalized
approach
is
based
on
genetically
engineering
cells
derived
from
the
patient
to
target
antigens
expressed—among
others—on
malignant
cells.
Nowadays
they
offer
new
hope
where
conventional
therapies,
such
as
chemotherapy
and
radiation,
have
often
failed.
Since
first
FDA
approval
in
2017,
CAR
rapidly
expanded,
proving
highly
effective
against
previously
refractory
diseases
with
otherwise
a
dismal
outcome.
Despite
its
promise,
continues
face
significant
challenges,
including
complex
manufacturing,
management
of
toxicities,
resistance
mechanisms
that
impact
long-term
efficacy,
limited
access
well
high
costs,
which
continue
shape
ongoing
research
clinical
applications.
review
aims
provide
an
overview
therapy,
fundamental
concepts,
applications,
current
future
directions
American Journal of Roentgenology,
Journal Year:
2024,
Volume and Issue:
222(3)
Published: March 1, 2024
Chimeric
antigen
receptor
(CAR)
T-cell
therapy
is
a
cellular
in
which
the
patient's
T
cells
are
enhanced
to
recognize
and
bind
specific
tumor
antigens.
CAR
was
initially
developed
for
treatment
of
leukemia,
but
its
current
main
indication
relapsed
or
refractory
non-Hodgkin
lymphoma.
FDG
PET/CT
plays
fundamental
role
diagnosis,
staging,
response
assessment,
recurrence
evaluation
patients
with
metabolically
active
Consistent
examination's
lymphoma
management,
also
imaging
modality
choice
evaluate
before
after
therapy,
evidence
supporting
utility
this
setting
continues
accumulate.
In
article,
we
review
concepts
lymphoma,
emphasizing
critical
therapy.
A
framework
presented
that
entails
performing
at
four
time
points
over
course
therapy:
pretherapy
baseline
decision
administer
any
bridging
therapies
posttherapy
1
3
months
infusion.
PET
parameters
assessed
these
predict
various
patient
outcomes.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(17), P. 9463 - 9463
Published: Aug. 30, 2024
Colorectal
cancer
(CRC)
represents
a
significant
global
health
burden,
with
high
incidence
and
mortality
rates
worldwide.
Recent
progress
in
research
highlights
the
distinct
clinical
molecular
characteristics
of
colon
versus
rectal
cancers,
underscoring
tumor
location's
importance
treatment
approaches.
This
article
provides
comprehensive
review
our
current
understanding
CRC
epidemiology,
risk
factors,
pathogenesis,
management
strategies.
We
also
present
intricate
cellular
architecture
colonic
crypts
their
roles
intestinal
homeostasis.
carcinogenesis
multistep
processes
are
described,
covering
conventional
adenoma-carcinoma
sequence,
alternative
serrated
pathways,
influential
Vogelstein
model,
which
proposes
sequential
BBA Advances,
Journal Year:
2025,
Volume and Issue:
7, P. 100149 - 100149
Published: Jan. 1, 2025
The
fundamental
biological
processes
involving
highly
specific
interactions
between
proteins
and
other
motifs
are
the
pillars
of
protein
recognition
mechanisms.
These
crucial
for
systems,
often
having
significant
implications
within
diagnostics
therapy
development.
Protein
specificity
reliant
on
structural
compatibility,
dynamic
conformational
changes,
biochemical
interactions-all
which
grounded
in
molecular
forces
like
hydrogen
bonding,
ionic
interactions,
van
der
Waals
forces.
Advanced
characterization
tools
have
improved
our
understanding
revealing
kinetics
thermodynamics
these
In
parallel,
new
computing
methods,
including
artificial
intelligence,
docking,
dynamical
simulations,
increased
prediction
accuracy
leading
to
well-defined
interaction
sites
binding
information.
is
pivotal
diagnostic
methods
ELISAs
biosensors,
disease
detection
applications.
therapeutics,
plays
an
important
role
drug
development,
enabling
design
small
molecules,
peptides,
monoclonal
antibodies.
Despite
recent
progress,
there
many
challenges
remaining
fully
understand
recognition,
particularly
complex
cell
environment.
require
future
work
studies
enhance
therapeutic
researchers
using
screening
identify,
assess,
optimize
clinical
translation.
Hämostaseologie,
Journal Year:
2025,
Volume and Issue:
45(01), P. 014 - 023
Published: Feb. 1, 2025
Abstract
Chimeric
antigen
receptor
(CAR)
T
cell
therapy
has
revolutionized
cancer
immunotherapy,
particularly
for
hematological
malignancies.
This
personalized
approach
is
based
on
genetically
engineering
cells
derived
from
the
patient
to
target
antigens
expressed—among
others—on
malignant
cells.
Nowadays
they
offer
new
hope
where
conventional
therapies,
such
as
chemotherapy
and
radiation,
have
often
failed.
Since
first
FDA
approval
in
2017,
CAR
rapidly
expanded,
proving
highly
effective
against
previously
refractory
diseases
with
otherwise
a
dismal
outcome.
Despite
its
promise,
continues
face
significant
challenges,
including
complex
manufacturing,
management
of
toxicities,
resistance
mechanisms
that
impact
long-term
efficacy,
limited
access
well
high
costs,
which
continue
shape
ongoing
research
clinical
applications.
review
aims
provide
an
overview
therapy,
fundamental
concepts,
applications,
current
future
directions
